Regeneron (NASDAQ:REGN) has built a formidableBusinesson a handful of blockbuster medicines, but its future depends on what comes next. As its older products face growing competition, pipeline progress, turning laboratory science into approved, saleable drugs, is crucial to itsNasdaq100 healthcare story.
SANGRIX INC. (NASDAQ: SGRX) is repositioning its public identity around AI computing infrastructure with a new corporate website, logo and investor-relations contact.
● Synergy CHC disclosed aNasdaqnotice on 20 August 2026 for failing to timely file its Form 10-Q for the quarter ended 30 June 2026, with a compliance plan due by 19 October 2026.
Vertex Pharmaceuticals (NASDAQ:VRTX) built a remarkableBusinessby dominating the treatment of a single rare disease, cystic fibrosis. Now the crucial question forNasdaq100 investors is whether it can repeat that success elsewhere, because itsLong-term Growthdepends on expanding beyond theFranchisethat made it, into new areas such as …
D.R. Horton, Inc. (NYSE: DHI) added $5.0 billion to its authorization for common-stock repurchases on September 15. The board-approved authorization has no expiration date.
Driven Brands Holdings Inc. (NASDAQ: DRVN) has authorized up to $100 million in common stock repurchases, adding shareholder returns to its updated capital allocation priorities. The authorization took effect on September 15, 2026, while the company continues to invest in Take 5 growth.
FG Nexus Inc. (NASDAQ: FGNX) has repurchased approximately 4.0 million common shares for approximately $48.0 million, including commissions. Those purchases represent approximately 46% of the shares outstanding immediately before the common-stock program began.
The materials will be available on the company’s investor-relations website and include discussion of cloud communications, AI voice and messaging.
Alnylam Pharmaceuticals (NASDAQ:ALNY) pioneered an entirely new class of medicine, drugs that silence disease-causing genes, and it is now turning that science into fast-growing commercial products. As those medicines reach more patients, Alnylam brings the promise of RNA-based therapies into theNasdaq100 growth debate, offering …
Nano Dimension Ltd. CFO Brenton John forfeited 17,029 shares at $1.54 per share. The transaction was recorded on September 14, 2026.